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Abstract: Feline Leukemia virus (FeLV) is a pathogenic retrovirus endemic among domestic cats, remaining a serious disease since 
its discovery in 1964. RNA interference (RNAi) is a process in which double-stranded RNA induces the post-transcriptional sequence-
specific degradation of homologous messenger RNA. At present, RNAi technology is regarded as a potential strategy for the treatment 
of various diseases as it can be used to inhibit the expression of desired peptides/proteins. This study aimed to apply RNAi technology 
to inhibit the replication of FeLV. We examined the effect of vector-mediated transfer and expression of FeLV specific short hairpin RNA 
(shRNA) against p27 protein expression and replication of FeLV in a feline T-cell line chronically infected with FeLV (3201-EECC). 
Three shRNA homologous to the FeLV gag gene were synthesized, cloned and transfected into a feline fibroblastic cell line (CrFK) 
expressing FeLV which efficiently reduced FeLV p27 protein expression, consequently decreasing and inhibiting the viral replication in 
a chronically FeLV infected feline T-cell line (3201-EECC). The expression of shRNA against FeLV gag gene showed markedly lower 
p27 levels and viral replication in both cell lines, 3201-EECC and CrFK. These results provide useful information to pave the road for 
the development of a gene therapy strategy to control FeLV and related pathogenic retrovirus infections in the future.
Keywords: RNA interference, FeLV, gag, p27, cat
Retrovirology: Research and Treatment 2012:4 13–20
Retrovirology: Research and Treatment 2012:4 13
Ornelas et al
Introduction
The Feline Leukemia Virus (FeLV) is a member of the 
Retroviridae family, sharing the genus gammaretrovirus 
with the Xenotropic Murine Leukemia Virus-related 
gammaretrovirus (MLV) and the Gibbon Ape Leukemia 
Retrovirus (GALV). FeLV is pathogenic for domestic 
cats and involved in proliferative, degenerative, and 
immunosuppressive disorders as well as immunodefi-
ciency, anemia and lymphoma.1–5 Since its discovery 
in 1964, FeLV remains a serious pathogen for domestic 
cats. Most FeLV infections occur after oronasal spread 
of the virus in the saliva of viremic cats.6,7 The world-
wide prevalence of FeLV infection is not well known. 
It is remarkably low among cats from single cat 
households with a prevalence of approximately 1% 
and higher than 20% in large, multi-cat households 
that do not practice preventative measures against the 
introduction of FeLV.8
FeLV is a simple retrovirus carrying the necessary 
genes for replication, lacking cancer-causing 
oncogenes. Nonetheless the virus is responsible for 
a large proportion of lymphoid and myeloid malig-
nancies in pet cats.1,2,6,8–13 The virus contains a diploid 
RNA genome, each strand encoding the three genes 
(gag, pol, and env) required for viral replication. The 
gag gene encodes the structural proteins of the virion 
core (p10, p15, and p27), the pol gene encodes an 
RNA-dependent DNA polymerase, and the env gene 
encodes the envelope glycoproteins of the virion 
surface.3,14
Cancer development promoted by the virus is 
hypothesized to occur in two main ways. In the first 
mechanism the virus acts through the insertional 
mutagenesis, activating cellular oncogenes driven 
by proviral sequences involved in virus replication.15 
A second mechanism has been termed transduction, by 
which the FeLV provirus acquires cellular oncogenes, 
such as myc, by recombination;12,16 such recombinant 
viruses can lead to rapid neoplasm development.10
In treating cats infected with FeLV, a timely and 
accurate identification of any diseases affecting the 
cat is necessary in order to provide an early therapeu-
tic intervention and provide for a successful outcome. 
Chemotherapeutic drugs, immune modulators, antivi-
rals, and vaccination should be combined to treat FeLV-
infected cats.8,17,18 Therapeutic procedures employing 
feline omega interferon (ω interferon) and aiming to 
curb FeLV viremia have been shown to improve the 
clinical condition significantly and extend the survival 
time of infected cats, although the procedures did not 
reverse viremia.10,19 An antiviral compound routinely 
used, 3′-azido-2′, 3′-dideoxythymidine (AZT), has 
been shown to reduce the plasma viral load, improve 
immunological and clinical status, increase quality 
of life, and prolong life expectancy in some FeLV-
infected cats.20 However, the manifestation of severe 
hematological side effects by the use of antiviral drugs 
and poor clinical improvements in FeLV-infected cats 
has also been reported.1,10 Cat vaccination is an essen-
tial preventive measure. However, it is unknown 
whether FeLV vaccines provide 100% protection 
efficacy, and none prevent infection.17 Therefore, any 
effective antiviral procedure for FeLV-infected cats is 
not yet established.16
RNA interference (RNAi) is a process of sequence 
specific, post-transcriptional gene silencing (PTGS) 
triggered by double-stranded RNA (dsRNA) homolo-
gous to the target transcripts.21 The reaction is initi-
ated by the introduction of a double-stranded RNA 
(dsRNA) into the cell cytoplasm, resulting in the 
destruction of targeted mRNA and a subsequent 
reduction in protein production.22 When success-
fully manipulated, the RNAi mechanism knocks 
down single or multiple genes, providing a quick and 
convenient method of analyzing gene function.23–29 
Recent studies have demonstrated that RNAi can 
be exploited in order to target genetic sequences of 
a variety of human and animal viruses including 
HIV-1, Poliovirus, Human Papillomavirus (HPV), 
Hepatitis C Virus (HCV), Hepatitis B Virus (HBV), 
Influenza Virus, Severe Acute Respiratory Syndrome 
Coronavirus (SARS-CoV), and Feline Immunodefi-
ciency Virus (FIV).9,30–39 These studies confirmed that 
RNAi technology represents a promising gene thera-
peutic approach to control viral infection and disease 
progression. Previous studies applying RNAi directed 
to structural genes inhibited viral replication of HIV 
and FIV.30–33,40
In this study, in order to investigate the potential 
use of RNAi technology as a therapeutic strategy for 
the control of FeLV replication, we first examined the 
expression of shRNAs against FeLV gag gene by the 
pSUPER vector system in FeLV replication in fibro-
blastic cells. Sequentially, we generated a retrovirus 
vector expressing a FeLV-specific shRNA and exam-
ined its effect on virus replication in a chronically 
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FeLV-infected feline T lymphoid cell line, aiming 
to evaluate the efficient delivery and expression of 
FeLV-specific shRNA and certify the persistent inhib-
itory effect of FeLV in these cells.
Material and Methods
cells
The NIH AIDS reagents and D Looney kindly donated 
a feline fibroblastic cell line (CrFK) and the Human 
293T cells, respectively. Dulbecco’s Modified Eagle 
Medium (DMEM) (Sigma, St Louis, MO) and RPMI 
1640 (45%), Leibovitz’s L-15 (45%) containing 
10% heat-inactivated fetal bovine serum (FBS), and 
penicillin/streptomycin (GIBCO) maintained estab-
lished cells including the feline T-cell line, 3201, 
chronically infected with FeLV-EECC (3201-EECC) 
NIH strain in the experiments.
Plasmid construction
The general guidelines22 oriented the design and 
synthesis (Invitrogen) of target sequences, there-
fore three selected sequences (F1, F2, and F3) 
corresponding to the gag gene of FeLV Rickard 
strain, subgroup A (GenBank accession number: 
AF052723), were based on the conserved sequence 
of FeLV gag gene. Table 1 shows sequences of sense 
and antisense strands directed to the FeLV gag gene. 
The oligonucleotides strands annealed and cloned 
into the pSUPER vector essentially as previously 
described39 to generate pH1-F1, pH1-F2 and pH1-F3 
constructs. The control (pH1-GFP) consisted of a tar-
get sequence described before9,38 against the Green 
Fluorescent Protein (GFP).4,22,39
The DNA sequences containing the H1 promoter 
and encoding specific shRNA were excised from the 
pSUPER vector by digestion with ClaI and XbaI, and 
subcloned into the same sites in the pNL-SINCMV-
BLR vector40,42,43 (kindly provided by Dr Bryan R 
Cullen) to generate the pNL-H1-F1 and pNL-H1-
GFP constructs as previously described.40 A similar 
lentivirus vector termed pNL-H, containing the H1 
promoter but lacking any shRNA precursor, was 
generated in parallel as a negative control.
crFK cells transfection
CrFK cells were co-transfected with 0.5 µg of 
pEECC-FeLV (NIH AIDS reagents) and 3.5 µg of 
pH1-F1, pH1-F2, pH1-F3 or pH1-GFP, respectively, 
utilizing the calcium phosphate method as previously 
described.44 The cells were plated at 2 × 105 cells per 
well (9.6 cm2) with DMEM in six-well plates for 
24 hours. The culture medium was replaced 16 hours 
later, and the supernatant media harvested approxi-
mately 48 hours post-transfection. After cell pel-
let lysis, the shRNA efficiency was analyzed by the 
immunoblotting detection of p27 protein expression 
or RT assay.
immunoblotting analysis
CrFK cells were harvested approximately 48 hours 
post-transfection and ressuspended in lysis buf-
fer (10 mM Tris-Cl [pH 7.5], 140 mM NaCl, 1 mM 
PMSF, 1% Triton X-100). Thirty micrograms of 
total obtained protein were electrophoresed on 10% 
polyacrylamide gel containing SDS.  Electroblotted 
proteins on PVDF membranes (Hybond P, GE 
Healthcare, Wien) were blocked overnight with 5% 
nonfat dry milk in TBS-T (20 mM Tris-Cl [pH 7.6], 
280 mM NaCl, 0.1% Tween-20) and incubated for 
1 hour at room temperature with goat anti-FeLV p27 
(diluted 1:2000; NCI Repository) or anti-GAPDH 
(diluted 1:500 in TBS-T containing 5% nonfat dry 
milk; FL-335; Santa Cruz Biotechnology). After 
washing, the membranes were incubated for 1 hour 
at room temperature with a secondary anti-goat or 
anti-mouse antibody conjugated with Alkaline Phos-
phatase (diluted in TBS-T 1:1000; abcam). Protein 
immunodetection was performed using NBT/BCIP 
Stock Solution (ROCHE) according to the manu-
facturer’s instructions. For analysis of the Western 
blotting data, densitometric analysis was performed 
using ImageJ software (NIH).
Table 1. Target sequences and corresponding regions in genome of FeLV-A clone.
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Preparation of virus stocks  
and transduced cells
The HIV-1-based lentivirus vectors expressing 
shRNAs were prepared by co-transfection of 293T 
cells with 1.8 µg of the lentivirus vector, 0.1 µg 
of pcRev, 0.1 µg of pcTat, and 50 ng of pHIT/G 
as previously described.40 The culture medium was 
replaced 16 hours later, and supernatant media was 
harvested approximately 48 hours post-transfection 
and passed through a filter with a pore size of 0.45 µm. 
Retroviral RNA was measured by the Reverse 
Transcriptase Assay.
A feline T-cell line chronically infected with FeLV, 3201-
EECC, was seeded into a 12-well plate at 2 × 105 cells/well 
and inoculated with the lentivirus vectors at a multiplicity 
of infection (MOI) of 10 in a final volume of 1 mL of 
RPMI 1640 (45%), Leibovitz’s L-15 medium (45%) 
supplemented with 10% heat-inactivated fetal bovine 
serum (FBS) and penicillin/streptomycin (GIBCO). After 
incubation at 37 °C for 48 hs, the cells were washed twice 
with PBS, and then cultured in the presence of 8 µg/mL 
of blasticidin S hydrochloride (Sigma) for 15 days to 
generate stably transduced cells.
Reverse transcriptase (RT) activity 
assay
FeLV particles were precipitated and concentrated 
with polyethylene glycol (PEG 6000). Initially, 3201 
EECC cells were centrifuged at 250 × g for 10 minutes 
to remove cell debris. Obtained supernatant was 
centrifuged at 2000 × g for 30 min. Sequentially, 
1 mL of PEG solution was added to 2 mL of cleared 
supernatant and incubated overnight at 4 °C. The pellet 
containing virions was obtained by centrifugation 
at 800 × g for 45 minutes and stored at −60 °C. All 
centrifugation procedures were carried out at 4 °C. 
Virions were lysed using 10% Triton X-100 (1% final 
concentration) in RPMI medium supplemented with 
10% FBS, and RT units were measured using EnzChek 
Reverse Transcriptase Assay Kit (Invitrogen). The 
assay was performed in triplicate.
Statistical analysis
Statistical significance was evaluated by one-way 
analysis of variance (ANOVA), which was used to test 
for a significant difference in each RT quantification. 
If a significant difference was found by ANOVA, a 
student’s t-test was performed to determine which 
pair showed the difference. Statistical significance 
was evaluated at P , 0.05.
Results
inhibition of p27 expression in crFK 
transfected cells
We examined the effect of three target sequences 
homologous to the FeLV gag gene (F1, F2, and F3) on the 
replication of FeLV in CrFK/FeLV cells. A sequence target 
homologous to GFP was used as a control. Immunoblotting 
analysis of cell extracts after approximately 48 hours 
post-transfection demonstrated the reduction of FeLV 
p27 protein expression in transfected cells with pH1-F1 
and pH1-F2 vectors compared to mock-transfected 
(pH1-GFP) cells (Fig. 1A). Among the three anti-FeLV 
shRNAs vector expression, pH1-F2 showed the strongest 
inhibitory effect on FeLV p27 protein expression in 
CrFK cells. The concentration of FeLV p27 was assessed 
by measuring the integrated density. The densitometric 
analysis confirmed p27 reduction after co-transfection 
of vectors expressing shRNA against gag with FeLV 
plasmid expression, exhibiting the F2 sequence a marked 
reduction of protein expression, as shown as 1.8 ± 0.38 
units for pH1-F2 with pEECC vs. 8.46 ± 1.12 units for 
pH1-GFP with pEECC expression (P , 0.05) (Fig. 1B).
effect of shRnAs expression on FeLV 
replication in crFK transfected cells
The inhibitory effect of anti-FeLV shRNA on FeLV 
replication in CrFK cells was evaluated by measuring 
RT activity in the supernatant of co-transfected cells 
with pEECC and pH1-GFP (Mock) or pH1-F1 or 
pH1-F2. Co-transfected cells with pH1-F2 showed 
significantly lower RT units than those of untreated 
cells, 0.25 ± 0.05 vs. 0.84 ± 0.12 RT units respectively 
and 0.41 ± 0.07 RT unit reduction in pH1-F1 
co-transfected cells (P , 0.05) (Fig. 2). These results 
indicated that shRNA against FeLV gag gene could 
specifically inhibit Feline Leukemia virions release 
from transfected cells.
effect of lentivirus vector-mediated 
expression of FeLV-specific shRNA on 
the FeLV replication in 3201-eecc cells
The efficiency of lentivirus vector-mediated transference 
and expression of FeLV-specific shRNA on FeLV 
replication was investigated in FeLV-infected T cells 
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(3201-EECC cells). The cells stably expressing shRNA 
after VSV-G pseudotyped lentivirus vector inoculation, 
were selected utilizing blasticidin. FeLV replication in 
these cells was examined during 15 days after inocula-
tion with the  lentivirus vectors. The RT activity measured 
in the supernatant of transduced cells with the lentivirus 
 vector carrying shRNA specific to FeLV (shF2) was 
 significantly lower (0.86 ± 0.11 units) than in untreated 
cells (3.04 ± 0.16 units) (P , 0.05), and in the infected 
cells with the lentivirus vector control with only the H1 
promoter (shH1) (2.41 ± 0.28 units) (Fig. 3).
Discussion
Since the RNAi technology has been developed, a 
plethora of genes from eucaryotes, prokaryotes, and 
viruses have been studied, and as a therapeutic tool, a 
variety of viral infections and diseases in humans and 
animals have been treated. The inhibition of HIV-1 
and FIV29–33,40,45,46 replication among other viruses 
could be accomplished by the shRNA expression in 
established and primary cell lines. Here, we investi-
gated the feasibility of using RNAi technology, based 
in shRNA expression, aiming at controlling FeLV 
infection in feline cell lines. The present study was 
carried out to demonstrate the potentiality of RNAi 
technology approach as a strategy for the control of 
FeLV infection, and to demonstrate that it is pos-
sible to reduce FeLV replication in vitro by RNAi 
 technology. A lentiviral vector expressing shRNA 


































































































Figure 1. (A) effect of shRnAs on the p27 protein expression in crFK/FeLV cells. Regulation of p27 protein expression in crFK cells transfected with 
peecc plasmid and shRnA expression vector against gag gene. The shRnA expression vector against gFP was used as a control. The immunoblotting 
assay was performed with polyclonal antibody against p27 and monoclonal antibody against GAPDH (as a control). The first line corresponded to the 
gAPDh levels in the cells and the second line corresponded to p27 levels in the cells. The p27 levels reduced in the presence of the ph1-F1 and ph1-F2 
vectors. (B) Densitometric analysis of p27 expression. The p27 protein content was determined by the immunoblotting analysis and data are expressed 
as integrated density in arbitrary units × 104. 
note: The columns and bars show means and standard deviations, respectively, obtained from the data in triplicate samples.
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developed and its effect examined upon the transfer-
ence into feline cell lines.
In order to identify the target sequence which can 
efficiently inhibit FeLV replication, the effects of 
homologous sequences to FeLV gag gene on FeLV 
co-transfected CrFK cells were investigated. Three 
homologous target sequences to gag gene were used 
to construct three clones against EECC-FeLV clone 
(pH1-F1, pH1-F2, and pH1-F3) and co-transfected 
with pEECC plasmid on CrFK transfected cells. 
We demonstrated that transfection with vectors 
expressing anti-FeLV shRNAs (F1 and F2) resulted 
in reduction of p27 protein expression (Fig. 1) and 
RT activity in the culture supernatant (Fig. 2), 
indicating that a region of FeLV gag gene can be 




























Figure 2. effect of shRnA expression on the releasing of FeLV in crFK cells. 
notes: The RT activity in the culture supernatants was measured approximately 48 hours after co-transfection with shRnA vector expression and peecc 
vector. The columns and bars show means and standard deviations, respectively, obtained from the data in triplicate samples. A target sequence gFP 























Figure 3. Effect of lentivirus vector-mediated transfer and expression of FeLV-specific shRNA on the replication of FeLV in 3201 EECC cells. 
notes: The cells were transduced with the lentivirus vector, which express shRnA (F2 target sequence) or only h1 promoter and then selected under 
blasticidin treatment. The RT activity in the culture supernatants were measured 15 days after lentivirus vector-mediated transfection. The columns and 
bars show means and standard deviations, respectively, obtained from the data in triplicate samples.
18 Retrovirology: Research and Treatment 2012:4
RnA interference of feline leukemia virus replication
like HIV and FIV, for example.30–33,40,41 The F3 vector 
expressing anti-FeLV shRNA failed to reduce p27 
protein expression, despite its complementarity to 
the gag sequence. Distinct factors could influence 
the inhibition mechanisms exerted by the anti-FeLV 
shRNA, including technical errors.
Lentiviral vectors can infect both dividing and 
nondividing cells, changing the expression of their 
target cell genes and being capable of providing 
highly effective gene therapy devices.47 Therefore, we 
examined the effect of the lentivirus vector mediated 
transfer and expression of the shRNA in feline T-cell 
line. The amount of RT activity in the culture supernatant 
of the 3201 EECC cell line were markedly decreased 
even 15 days after transduction with a lentiviral vector 
which expresses shRNA specific to FeLV (pNL H1-F2) 
(Fig. 3). This reduction in RT activity observed in 
chronically FeLV-infected cell line, 3201, supports a 
future use of this tool in FeLV gene therapy. However, 
while the interference RNA virus escape was observed 
in other virus systems,48,49 in the FeLV system the 
results could be distinct as significant changes in FeLV 
render the virus less viable than FIV and HIV.3 In this 
case, the shRNA could be a new treatment strategy in 
the future for FeLV infected cats.
Further investigation is necessary to improve the 
transduction efficiency of the lentivirus vector in 
primary T cells of cats. Additionally, hematopoietic 
stem cells are promising target candidates for 
RNAi gene therapy to control FeLV infection. The 
development of antiviral gene therapy strategies 
targeting these cells has been proposed as a long-
term treatment for AIDS. Nevertheless, the isolation 
and purification system of feline hematopoietic stem 
cells has not been established, and the viral vector-
mediated transfer of anti-FeLV shRNA and other 
genes into these cells will probably be a useful gene 
therapy strategy for the control of FeLV infection and 
treatment of infected cats in the future.
The goal of the gene therapy strategy for the 
control of FeLV infection is to achieve FeLV-resistant 
hematopoietic cells and/or inhibit the disease 
progression. It is highly plausible that the F2 target 
sequence inhibits the replication of various FeLV field 
strains as well as the EECC strain and may be used to 
protect the cells. Gene silencing by RNAi mechanism 
requires almost perfect complementarity between 
the shRNA and target sequence besides clinical trials 
would result differently from in vitro studies. The 
efficacy of shRNA generated in this research study 
needs to be investigated in other FeLV strains. In 
any case, this work demonstrates the reduction of 
FeLV infection by the RNAi technology and opens 
an opportunity to continue experiments aimed at 
developing experimental gene therapy models.
conclusions
In summary, we demonstrated that expression of shRNAs 
homologous to the FeLV gag gene efficiently inhibited 
p27 expression and FeLV replication in the CrFK cell line. 
In addition, we showed that lentivirus vector-mediated 
transfer and expression of FeLV-specific shRNA could 
inhibit virus replication in chronically infected FeLV 
lymphoid cells. The present study indicated that the 
RNAi technology could be useful as a gene therapy 
strategy for the control of FeLV infection.
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